medigraphic.com
ISSN 0016-3813 (Impreso)

2016, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2016; 152 (3)


Prevalencia de trastornos neuropsiquiátricos en pacientes con enfermedad de Parkinson (EP) no tratados

Isais-Millán S, Piña-Fuentes D, Guzmán-Astorga C, Cervantes-Arriaga A, Rodríguez-Violante M

Idioma: Español
Referencias bibliográficas: 30
Paginas: 357-363
Archivo PDF: 87.45 Kb.


RESUMEN

Introducción: La EP se acompaña por un amplio espectro de manifestaciones neuropsiquiátricas. Su fisiopatología ha sido asociada a alteraciones propias de la enfermedad, así como también al tratamiento dopaminérgico. Material y métodos: Se realizó un estudio transversal en pacientes con EP temprana no expuestos a ningún tratamiento de reemplazo dopaminérgico. Todos los participantes fueron evaluados a través de un conjunto de escalas específicas para síntomas neuropsiquiátricos incluyendo: cognición, depresión, ansiedad, apatía, psicosis y trastorno de control de impulsos. Resultados: Se incluyeron un total de 63 pacientes con Parkinson, de los cuales 26 (41.3%) sujetos presentaban algún grado de deterioro cognitivo, 7 (11.1%) presentaban depresión y 11 (15.8%) sujetos presentaban ansiedad. En relación a los demás síntomas, un total de 12 (19%) sujetos presentaba apatía, 7 (11.1%) psicosis y 8 (12.6%) pacientes presentaban síntomas de trastorno del control de impulsos. Conclusión: Los trastornos neuropsiquiátricos son frecuentes en pacientes con EP temprana sin tratamiento dopaminérgico. Dado el impacto en la calidad de vida es indispensable su identificación y tratamiento oportuno.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Ann Neurol. 1998;44:S1-9.

  2. Glosser G, Clark C, Freundlich B, Kliner-Krenzel L, Flaherty P, Stern M. A controlled investigation of current and premorbid personality: characteristics of Parkinson’s disease patients. Mov Disord. 1995;10:201-6.

  3. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:492-6.

  4. Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson’s disease: expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013;31:S1-16.

  5. Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf. 2014;13:1055-69.

  6. Gibb WR, Lees AJ. The relevance of the lewy body to the pathogenesis of idiopathic parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988; 51:745-52.

  7. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.

  8. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020-8.

  9. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26:353-7.

  10. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord. 2014; 20:1145-8.

  11. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005;187:366-71.

  12. Llanero-Luque M, Ruiz-Sánchez de León JM, Pedrero-Pérez EJ, et al. Sintomatología disejecutiva en adictos a sustancias en tratamiento mediante la versión española del cuestionario disejecutivo (DEX-Sp). Rev Neurol. 2008;47:457-63.

  13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-70.

  14. Sockeel P, Dujardin K, Devos D, Deneve C, Destée A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:579-84.

  15. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive‐compulsive disorders in Parkinson’s Disease– Rating Scale. Mov Disord. 2012;27:242-7.

  16. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716-22.

  17. Meyer PT, Frings L, Hellwig S. Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases. Curr Opin Neurol. 2014;27:398-404.

  18. Garcia-Diaz AI, Segura B, Baggio HC, et al. Structural MRI correlates of the MMSE and pentagon copying test in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:1405-10.

  19. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26:1814-24.

  20. Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive Performance and Neuropsychiatric Symptoms in Early, Untreated Parkinson’s Disease. Mov Disord. 2015;30:919-27.

  21. Nazem S, Siderworf AD, Duda J, et al. Montreal Cognitive Assessment performance in patients with Parkinson’s disease with “normal” global cognition according to Mini-Mental State Examination score. J Am Geriatrics Soc. 2009;57:304-8.

  22. Ceravolo R, Pagni C, Tognoni G, Bonuccelli U. The epidemiology and clinical manifestations of dysexecutive syndrome in Parkinson’s disease. Front Neurol. 2012;3:159.

  23. Gama RL, de Bruin VM, de Bruin PF, et al. Risk factors for visual hallucinations in patients with Parkinson’s disease. Neurol Res. 2015;37:112-6.

  24. Papapetropoulos S, Katzen H, Shrag A, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol. 2008;8:21.

  25. Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:708-15.

  26. Dujardin K, Langlois C, Plomhause L, et al. Apathy in untreated early- stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord. 2014;29:1796-801.

  27. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227-32.

  28. Zhang G, Zhang Z, Liu L, et al. Impulsive and compulsive behaviors in Parkinson’s disease. Front Aging Neurosci. 2014;6:318.

  29. Giovannoni G, O’Sullivan J, Turner K, Manson A, Lees A. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68: 423-8.

  30. Grover S, Somaiya M, Kumar S, Avasthi A. Psychiatric aspects of Parkinson’s disease. J Neurosci Rural Pract. 2015;6:65-76.




2020     |     www.medigraphic.com